Exact Mass: 559.1572596
Exact Mass Matches: 559.1572596
Found 62 metabolites which its exact mass value is equals to given mass value 559.1572596
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
dTDP-D-desosamine
dTDP-beta-L-evernosamine
dTDP-4-ethylamino-3-O-methyl-2,4-dideoxy-L-threo-pentopyranose
Neoacrimarine K
Neoacrimarine K is found in citrus. Neoacrimarine K is an alkaloid from the roots of Citrus paradisi (grapefruit). Alkaloid from the roots of Citrus paradisi (grapefruit). Neoacrimarine K is found in citrus.
Gadoteridol
C17H29GdN4O7 (559.1277253999999)
Gadoteridol provides contrast enhancement of the brain, spine and surrounding tissues resulting in improved visualization (compared with unenhanced MRI) of lesions with abnormal vascularity or those thought to cause a disruption of the normal blood brain barrier. Gadoteridol can also be used for whole body contrast enhanced MRI including the head, neck, liver, breast, musculoskeletal system and soft tissue pathologies. n MRI, visualization of normal and pathological brain tissue depends in part on variations in the radiofrequency signal intensity that occur with changes in proton density, alteration of the T1, and variation in T2. When placed in a magnetic field, gadoteridol shortens the T1 relaxation time in tissues where it accumulates. Abnormal vascularity or disruption of the blood-brain barrier allows accumulation of gadoteridol in lesions such as neoplasms, abscesses, and subacute infarcts. V - Various > V08 - Contrast media > V08C - Magnetic resonance imaging contrast media > V08CA - Paramagnetic contrast media
Infigratinib
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors > L01EN - Fibroblast growth factor receptor (fgfr) tyrosine kinase inhibitors C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C164035 - FGFR-targeting Agent C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C155727 - FGFR Inhibitor C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor D000970 - Antineoplastic Agents
Acetic acid, 2-(4-((5-methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)sulfinyl)-1H-benzimidazol-1-yl)sulfonyl)phenoxy)-
8-(5-Chloro-2-(4-methylpiperazin-1-yl)isonicotinamido)-1-(4-fluorophenyl)-4,5-dihydro-1H-benzo[g]indazole-3-carboxamide
Cys Asp His Trp
Cys Asp Trp His
Cys His Asp Trp
Cys His Trp Asp
Cys Trp Asp His
Cys Trp His Asp
Asp Cys His Trp
Asp Cys Trp His
Asp His Cys Trp
Asp His Trp Cys
Asp Trp Cys His
Asp Trp His Cys
His Cys Asp Trp
His Cys Trp Asp
His Asp Cys Trp
His Asp Trp Cys
His Trp Cys Asp
His Trp Asp Cys
Trp Cys Asp His
Trp Cys His Asp
Trp Asp Cys His
Trp Asp His Cys
Trp His Cys Asp
Trp His Asp Cys
Gadoteridol
C17H29GdN4O7 (559.1277253999999)
V - Various > V08 - Contrast media > V08C - Magnetic resonance imaging contrast media > V08CA - Paramagnetic contrast media
Neoacrimarine K
4-(4-METHYLTHIOPHEN-2-YL)-N-(4-(MORPHOLINOMETHYL)PHENYL)-7-TOSYL-7H-PYRROLO[2,3-D]PYRIMIDIN-2-AMINE
LY2608204
D020536 - Enzyme Activators
1-Methyl-3-Tetradecylimidazolium Bis(Trifluoromethylsulfonyl)Imide
C20H35F6N3O4S2 (559.1973062000001)
DIMETHYL 2-(5-CYANO-5-FORMYL-2,6-BIS((2-METHOXYETHOXY)METHOXY)-[1,1-BIPHENYL]-3-YL)SUCCINATE
2-(dimethylamino)-2-biphenylyl-palladium(ii) chloride dinorbornylphosphine complex
C28H37ClNPPd (559.1386752000001)
7-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazine (-)-mandelate
4-Methylumbelliferyl 3,4,6-tri-O-acetyl-2-deoxy-2-trifluoroacetamido-b-D-glucopyranoside
8-(5-Chloro-2-(4-methylpiperazin-1-yl)isonicotinamido)-1-(4-fluorophenyl)-4,5-dihydro-1H-benzo[g]indazole-3-carboxamide
Infigratinib
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors > L01EN - Fibroblast growth factor receptor (fgfr) tyrosine kinase inhibitors C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C164035 - FGFR-targeting Agent C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C155727 - FGFR Inhibitor C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor D000970 - Antineoplastic Agents
[6-(Diethylamino)-9-(2,4-disulfophenyl)xanthen-3-ylidene]-diethylazanium
Gadolinium-HP-Do 3A
C17H29GdN4O7 (559.1277253999999)
V - Various > V08 - Contrast media > V08C - Magnetic resonance imaging contrast media > V08CA - Paramagnetic contrast media
2-[(2R,4aS,12aS)-5-methyl-6-oxo-8-(2,2,2-trifluoroethylsulfonylamino)-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-2-yl]-N-(3-fluorophenyl)acetamide
2-amino-4-({1-[(carboxymethyl)-C-hydroxycarbonimidoyl]-2-{[1-(6,7-dimethoxy-2H-1,3-benzodioxol-5-yl)-2-hydroxy-3-oxopropyl]sulfanyl}ethyl}-C-hydroxycarbonimidoyl)butanoic acid
C22H29N3O12S (559.1471874000001)